Nascent Biotech Presents at the July Emerging Growth Conference

July 30, 2024 8:00 AM

Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies targeting various cancer types, is pleased to provide an overview of the Company's presentation at The Emerging Growth Conference on July 18, 2024.Click here to view the Company's entire presentation.NBIO CEO, Sean Carrick, and other Biotechnology Innovators, were interviewed during the...

Read more

CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies

July 30, 2024 7:00 AM

Strategic in-license from Cortice Bioscience is highly synergistic with the ongoing potentially pivotal Berubicin program and demonstrates further commitment to changing the treatment paradigm in GBMDrug candidate, TPI 287, awarded Orphan designation and studied in over 350 patients to date, including clinical trials as monotherapy and in combination with bevacizumab demonstrating encouraging clinical efficacy and safety profile at target...

Read more

Interactive Strength Inc. (Nasdaq: TRNR) Secures Exclusive Distribution for CLMBR in Germany and Receives Six-Figure Initial Order

July 30, 2024 7:00 AM

Interactive Strength Inc. (NASDAQ:TRNR) ("TRNR" or "the Company"), maker of innovative specialty fitness equipment under the CLMBR and FORME brands, today announced that it has secured exclusive distribution and a six-figure initial order for CLMBR in Germany, the largest fitness market outside the United States.Trent Ward, Co-Founder and CEO of TRNR, said: "Germany is the largest international fitness market and we are confident of the demand...

Read more

Envision Pharma Group Announces the Appointment of Bill Shirey to President of Life Science Commercialization

July 30, 2024 7:00 AM

FAIRFIELD, CT / ACCESSWIRE / July 30, 2024 / Envision Pharma Group (Envision) announced today the appointment of Bill Shirey as President of Life Science Commercialization. Overseeing the Two Labs and Riparian brands, Bill will focus on enhancing Envision's commercialization and compliance solutions, delivering customized strategies that help bring pharmaceutical products to market and maintain compliance across the product lifecycle through...

Read more

3Aware Welcomes Prashant Thumma as First Chief Technology Officer

July 30, 2024 6:00 AM

INDIANAPOLIS, ID / ACCESSWIRE / July 30, 2024 / 3Aware, a leader in real-time surveillance and data solutions for medical technology, is pleased to announce the appointment of Prashant Thumma as its first Chief Technology Officer (CTO). Mr. Thumma brings a wealth of experience in technology leadership and innovation, poised to drive 3Aware's strategic growth.Thumma joins 3Aware with a distinguished career in health information technology. In his...

Read more

VGTNYC Weed Delivery Service Launches City-Wide Food Drive to Support 'City Harvest'

July 29, 2024 4:05 PM

VGTNYC Weed Delivery service NYC now accepting food-drive doorstep pick-up services, with matched donatios.NEW YORK, NY / ACCESSWIRE / July 29, 2024 / Vibrant community organization by VGTNYC is set to host its first-ever NY-wide food drive to support renowned hunger relief organization, 'City Harvest'. Bolstering its efforts to curb city-wide hunger, the food drive, which is ongoing throughout the month of August, This weed delivery service...

Read more

CORRECTING AND REPLACING: Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Annual mRNA-based Therapeutics Summit

July 29, 2024 11:57 AM

Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, will present a poster at the 4th Annual mRNA-based Therapeutics Summit taking place July 29 - 31, 2024, in Boston. The poster presents the Company's Linea™ IVT platform - a combination of an enzymatically produced DNA template (Linea™ DNA IVT template) coupled with a next-generation RNA polymerase - as a solution to enable mRNA producers to...

Read more

Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Presentation Annual mRNA-based Therapeutics Summit

July 29, 2024 11:10 AM

Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, will present a poster at the 4th Annual mRNA-based Therapeutics Summit taking place July 29 - 31, 2024, in Boston. The poster presents the Company's Linea™ IVT platform - a combination of an enzymatically produced DNA template (Linea™ DNA IVT template) coupled with a next-generation RNA polymerase - as a solution to enable mRNA producers to...

Read more

Physiowell's Holistic Path to Wellness: Empowering Everybody

July 29, 2024 10:45 AM

DUBAI, UAE / ACCESSWIRE / July 29, 2024 / It's difficult to remain current with your health and wellness journey amidst today's fast-moving world. Fortunately, Physiowell delivers a complete and holistic health approach, which empowers every individual toward the attainment of maximum well-being. In offering a range of therapies while dispensing tailored care, Physiowell gives every person the essential resources to succeed both physically and...

Read more

New Research Supports PillSafe’s Methodology in Reducing the Risk of Medication Misuse and Overuse

July 29, 2024 10:00 AM

The study raises concerns that overprescribing medications and the resulting unused medication are drivers of opioid misuse.EDMOND, OK / ACCESSWIRE / July 29, 2024 / In light of recent research published in the Canadian Medical Association Journal, PillSafe's smart pill delivery system targets the critical issues of unused prescriptions and patient medicine compliance, which the study identifies as key factors driving opioid misuse. This...

Read more

IntoValue, Inc Welcomes Brian Marcotte to Board of Directors

July 29, 2024 9:00 AM

IntoValue, Inc, proudly announces the appointment of Brian Marcotte to its Board of Directors.WASHINGTON, DC / ACCESSWIRE / July 29, 2024 / IntoValue, Inc, a groundbreaking healthcare direct-to-employer technology enablement company, proudly announces the appointment of Brian Marcotte to its Board of Directors. IntoValue logo for IntoValue Brian Marcotte brings a wealth of executive leadership experience to IntoValue, having served as President...

Read more

Avinger to Announce Second Quarter 2024 Results on August 8, 2024

July 29, 2024 8:45 AM

Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the second quarter 2024 after the close of trading on Thursday, August 8, 2024. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.To join the call by telephone,...

Read more

NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge

July 29, 2024 7:00 AM

ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL / ACCESSWIRE / July 29, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) ("NLS"), a biopharmaceutical company. and Kadimastem Ltd ("KDST.TA", "Kadimastem"), a clinical-stage cell therapy company developing and manufacturing "off-the-shelf" allogeneic cell products for the treatment of neurodegenerative diseases and potential cure of diabetes, announced today that they have entered into a binding term sheet...

Read more

Intraoral Scanner Market Is Expected to Reach USD 1,548.0 Million by 2034 And Grow at A CAGR of 7.6% | Future Market Insights, Inc.

July 29, 2024 6:00 AM

The intraoral scanner market size is poised to cross USD 744.7 million in 2024 and is likely to attain a valuation of USD 1,548.0 million by 2034. The intraoral scanner industry is projected to thrive at a CAGR of 7.6% from 2024 to 2034.Robot-assisted intraoral scanners, which employ robotic arms or automated positioning devices, improve scanning precision while reducing human variability. This development indicates a shift toward more...

Read more

Hemogenyx Pharmaceuticals PLC Announces Macrophage-Directed Therapies Summit Presentation

July 29, 2024 2:00 AM

Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company")(LSE:HEMO), the clinical-stage biopharmaceutical group developing treatments for cancers and viral diseases, is pleased to announce its participation in the 6th Macrophage-Directed Therapies Summit ("Summit"), which will be held on October 1-3, 2024, in Boston, MA. The Company will present its work on its proprietary Chimeric Bait Receptor ("CBR") platform.The Company's...

Read more

International OCD Foundation Honors Reality Star Scheana Shay for Raising OCD Awareness

July 28, 2024 7:15 PM

ORLANDO, FL / ACCESSWIRE / July 28, 2024 / Reality television sensation Scheana Shay received international accolades Saturday, July 27, for her advocacy in raising awareness about postpartum obsessive compulsive disorder (OCD), winning the International OCD Foundation (IOCDF) Illumination Award. The IOCDF Illumination Award honors media personalities who have represented OCD in a respectful, accurate, and appropriate way, or who have challenged...

Read more

Jolt Health Inc. Financing Update

July 26, 2024 5:00 PM

VANCOUVER, BC / ACCESSWIRE / July 26, 2024 / Jolt Health Inc. ("JOLT" and or "the Company") (CSE:JOLT)(FSE:G1Q0) announced that there was an error in the press release issued July 25, 2024. The Company will be issuing a total of 83,333,333 units at a price of $0.006 per unit, not 583,333,333 units as previously stated.About Jolt Health Inc.Jolt Health Inc. (CSE:JOLT) is a leading life sciences company focused on healthcare, biotechnology and...

Read more

Poolbeg Pharma PLC Announces Voluntary Delisting from OTCQB Market

July 26, 2024 2:00 AM

LONDON, UK / ACCESSWIRE / July 26, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it is voluntarily delisting its ordinary shares ("Ordinary Shares") from trading on the OTCQB Market due to low trading volume and the associated administrative...

Read more

Jolt Health Inc. Announces Financing

July 25, 2024 5:00 PM

VANCOUVER, BC / ACCESSWIRE / July 25, 2024 / Jolt Health Inc. ("JOLT" and or "the Company") (CSE:JOLT)(FSE:G1Q0) announced it is undertaking a non-brokered private placement of up to $500,000. The Company will issue up to 583,333,333 units at a price of $0.006 per unit. Each unit consists of one common share and one half of a common share warrant. Each whole warrant entitles the holder to subscribe for one additional common share for a period of...

Read more

Cosmos Health Successfully Submits Tender for C-Scrub Wash Chlorhexidine 4% to Supply NHS Scotland

July 25, 2024 2:45 PM

CHICAGO, IL / ACCESSWIRE / July 25, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its wholly-owned subsidiary, Decahedron Ltd ("Decahedron"), has...

Read more